Rationale, study design, and analysis plan of the Alveolar Recruitment for ARDS Trial (ART): Study protocol for a randomized controlled trial

Carregando...
Imagem de Miniatura
Citações na Scopus
27
Tipo de produção
article
Data de publicação
2012
Título da Revista
ISSN da Revista
Título do Volume
Editora
BIOMED CENTRAL LTD
Autores
BERWANGER, Otavio
TALLO, Fernando S.
REZENDE, Ederlon A. C.
TELLES, Jose M. M.
ROMANO, Edson
GUIMARAES, Helio P.
REGENGA, Marisa M.
TAKAHASHI, Luzia N.
Citação
TRIALS, v.13, article ID 153, 14p, 2012
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background: Acute respiratory distress syndrome (ARDS) is associated with high in-hospital mortality. Alveolar recruitment followed by ventilation at optimal titrated PEEP may reduce ventilator-induced lung injury and improve oxygenation in patients with ARDS, but the effects on mortality and other clinical outcomes remain unknown. This article reports the rationale, study design, and analysis plan of the Alveolar Recruitment for ARDS Trial (ART). Methods/Design: ART is a pragmatic, multicenter, randomized (concealed), controlled trial, which aims to determine if maximum stepwise alveolar recruitment associated with PEEP titration is able to increase 28-day survival in patients with ARDS compared to conventional treatment (ARDSNet strategy). We will enroll adult patients with ARDS of less than 72 h duration. The intervention group will receive an alveolar recruitment maneuver, with stepwise increases of PEEP achieving 45 cmH(2)O and peak pressure of 60 cmH2O, followed by ventilation with optimal PEEP titrated according to the static compliance of the respiratory system. In the control group, mechanical ventilation will follow a conventional protocol (ARDSNet). In both groups, we will use controlled volume mode with low tidal volumes (4 to 6 mL/kg of predicted body weight) and targeting plateau pressure <= 30 cmH2O. The primary outcome is 28-day survival, and the secondary outcomes are: length of ICU stay; length of hospital stay; pneumothorax requiring chest tube during first 7 days; barotrauma during first 7 days; mechanical ventilation-free days from days 1 to 28; ICU, in-hospital, and 6-month survival. ART is an event-guided trial planned to last until 520 events (deaths within 28 days) are observed. These events allow detection of a hazard ratio of 0.75, with 90% power and two-tailed type I error of 5%. All analysis will follow the intention-to-treat principle. Discussion: If the ART strategy with maximum recruitment and PEEP titration improves 28-day survival, this will represent a notable advance to the care of ARDS patients. Conversely, if the ART strategy is similar or inferior to the current evidence-based strategy (ARDSNet), this should also change current practice as many institutions routinely employ recruitment maneuvers and set PEEP levels according to some titration method.
Palavras-chave
Acute respiratory distress syndrome, Alveolar recruitment, PEEP, Clinical trials, Randomized
Referências
  1. BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818
  2. Borges JB, 2006, AM J RESP CRIT CARE, V174, P268, DOI 10.1164/rccm.200506-97OC
  3. Brower RG, 2004, NEW ENGL J MED, V351, P327
  4. Chiumello D, 1999, AM J RESP CRIT CARE, V160, P109
  5. de Matos GFJ, 2012, CRIT CARE, V16, DOI 10.1186/cc10602
  6. Esteban A, 2002, JAMA-J AM MED ASSOC, V287, P345, DOI 10.1001/jama.287.3.345
  7. Fan E, 2008, AM J RESP CRIT CARE, V178, P1156, DOI 10.1164/rccm.200802-335OC
  8. Gattinoni L, 2010, CRIT CARE MED, V38, pS539, DOI 10.1097/CCM.0b013e3181f1fcf7
  9. Grasso S, 2007, AM J RESP CRIT CARE, V176, P761, DOI 10.1164/rccm.200702-1930C
  10. Herridge MS, 2011, NEW ENGL J MED, V364, P1293, DOI 10.1056/NEJMoa1011802
  11. Herridge MS, 2003, NEW ENGL J MED, V348, P683, DOI 10.1056/NEJMoa022450
  12. Hodgson CL, 2011, CRIT CARE, V15, DOI 10.1186/cc10249
  13. Montori VM, 2005, JAMA-J AM MED ASSOC, V294, P2203, DOI 10.1001/jama.294.17.2203
  14. Mueller PS, 2007, ANN INTERN MED, V146, P878
  15. MUSCEDERE JG, 1994, AM J RESP CRIT CARE, V149, P1327
  16. Phua J, 2009, AM J RESP CRIT CARE, V179, P220, DOI 10.1164/rccm.200805-722OC
  17. Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
  18. Tremblay L, 1997, J CLIN INVEST, V99, P944, DOI 10.1172/JCI119259
  19. Villar J, 2006, CRIT CARE MED, V34, P1311, DOI 10.1097/01.CCM.0000215598.84885.01
  20. 1999, AM J RESP CRIT CARE, V160, P2118